{"id":"gsk2118436","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperkeratosis"},{"rate":null,"effect":"Palmar-plantar erythrodysesthesia"},{"rate":null,"effect":"Pyrexia"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Secondary malignancies"}]},"_chembl":{"chemblId":"CHEMBL2028663","moleculeType":"Small molecule","molecularWeight":"519.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GSK2118436 (dabrafenib) selectively inhibits BRAF kinase with high potency against the V600E mutation commonly found in melanoma. By blocking this oncogenic driver mutation, the drug suppresses the MAPK/ERK pathway that promotes melanoma cell proliferation and survival. This targeted approach is particularly effective in BRAF V600E-mutant melanomas.","oneSentence":"GSK2118436 is a BRAF V600E inhibitor that blocks mutant BRAF kinase signaling in melanoma cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:47:15.927Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma with BRAF V600E mutation"},{"name":"Unresectable melanoma with BRAF V600E mutation"}]},"trialDetails":[{"nctId":"NCT01989585","phase":"PHASE1, PHASE2","title":"Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-03-24","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Malignant Solid Neoplasm","enrollment":75},{"nctId":"NCT07485569","phase":"PHASE1","title":"Drug Repurposing in Thyroid Carcinoma: a Feasibility Trial","status":"NOT_YET_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2026-06-01","conditions":"Thyroid Cancer Stage IV, Anaplastic Thyroid Cancer, Differentiated Thyroid Cancer","enrollment":10},{"nctId":"NCT02196181","phase":"PHASE2","title":"Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-19","conditions":"Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma","enrollment":280},{"nctId":"NCT03919071","phase":"PHASE2","title":"Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-02-20","conditions":"Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma","enrollment":58},{"nctId":"NCT02465060","phase":"PHASE2","title":"Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-17","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma","enrollment":6452},{"nctId":"NCT04557956","phase":"PHASE1, PHASE2","title":"Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-19","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma","enrollment":16},{"nctId":"NCT04439292","phase":"PHASE2","title":"Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-08-12","conditions":"Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm","enrollment":35},{"nctId":"NCT06475989","phase":"PHASE3","title":"Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2024-08-22","conditions":"Refractory Differentiated Thyroid Gland Carcinoma","enrollment":264},{"nctId":"NCT03244956","phase":"PHASE2","title":"Efficacy of MEK (Trametinib) and BRAFV600E (Dabrafenib) Inhibitors With Radioactive Iodine (RAI) for the Treatment of Refractory Metastatic Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2017-12-27","conditions":"Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation","enrollment":40},{"nctId":"NCT02693535","phase":"PHASE2","title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","status":"RECRUITING","sponsor":"American Society of Clinical Oncology","startDate":"2016-03-14","conditions":"Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors","enrollment":4200},{"nctId":"NCT03091257","phase":"PHASE1","title":"A Study of Dabrafenib and/or Trametinib in Patients With Relapsed and/or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-06-21","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT07110246","phase":"PHASE2","title":"Dabrafenib and Trametinib for BRAF V600 Mutant Low-Grade Gliomas","status":"RECRUITING","sponsor":"University of California, San Francisco","startDate":"2025-11-07","conditions":"BRAF V600 Mutation, Low-grade Glioma, Low Grade Glioma of Brain","enrollment":96},{"nctId":"NCT04527549","phase":"PHASE2","title":"Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma","status":"TERMINATED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-06-01","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","enrollment":5},{"nctId":"NCT07448480","phase":"","title":"Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2026-02-01","conditions":"Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma","enrollment":1000},{"nctId":"NCT07440290","phase":"PHASE2, PHASE3","title":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.","status":"NOT_YET_RECRUITING","sponsor":"Cancer Research UK","startDate":"2026-02","conditions":"Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders","enrollment":30},{"nctId":"NCT04675710","phase":"PHASE2","title":"Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-06-24","conditions":"Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma","enrollment":30},{"nctId":"NCT07419932","phase":"","title":"Response to Neoadjuvant Treatment in Locally Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-12-23","conditions":"Thyroid Cancer, Thyroid Neoplasms","enrollment":120},{"nctId":"NCT04666272","phase":"","title":"Effectiveness and Safety of Dabrafenib in Combination With Trametinib as Adjuvant Treatment for Chinese Patients With Stage III BRAF V600 Mutation-positive Melanoma After Complete Resection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2020-12-31","conditions":"Melanoma","enrollment":78},{"nctId":"NCT02224781","phase":"PHASE3","title":"Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-09-08","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma","enrollment":267},{"nctId":"NCT03975829","phase":"PHASE4","title":"Pediatric Long-Term Follow-up and Rollover Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-11-04","conditions":"Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma","enrollment":163},{"nctId":"NCT02231775","phase":"PHASE2","title":"Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-22","conditions":"Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7","enrollment":58},{"nctId":"NCT04903119","phase":"PHASE1","title":"Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma","status":"RECRUITING","sponsor":"Rina Plattner","startDate":"2022-06-01","conditions":"Metastatic Melanoma, BRAF Gene Mutation","enrollment":30},{"nctId":"NCT04201457","phase":"PHASE1, PHASE2","title":"A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pediatric Brain Tumor Consortium","startDate":"2020-01-17","conditions":"Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1","enrollment":57},{"nctId":"NCT03340506","phase":"PHASE4","title":"Dabrafenib and/or Trametinib Rollover Study","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-28","conditions":"Melanoma, Non Small Cell Lung Cancer, Solid Tumor","enrollment":100},{"nctId":"NCT04452877","phase":"PHASE2","title":"A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-08-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":40},{"nctId":"NCT06262919","phase":"","title":"Special Drug Use-results Surveillance of Tafinlar/Mekinist","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-09","conditions":"BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor","enrollment":110},{"nctId":"NCT04294160","phase":"PHASE1","title":"A Study of Select Drug Combinations in Adult Patients With Advanced/Metastatic BRAF V600 Colorectal Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-22","conditions":"BRAF V600 Colorectal Cancer","enrollment":122},{"nctId":"NCT04489433","phase":"","title":"Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma","status":"NO_LONGER_AVAILABLE","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":"Melanoma","enrollment":""},{"nctId":"NCT05868629","phase":"","title":"Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-06","conditions":"Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors","enrollment":40},{"nctId":"NCT02910700","phase":"PHASE2","title":"Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-12-09","conditions":"Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7","enrollment":52},{"nctId":"NCT01972347","phase":"PHASE2","title":"Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2014-10-01","conditions":"Melanoma","enrollment":35},{"nctId":"NCT07256184","phase":"","title":"Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2022-11-15","conditions":"Metastatic Malignant Melanoma","enrollment":232},{"nctId":"NCT04961619","phase":"","title":"Adjuvant Dabrafenib and Trametinib Treatment in Patients With Completely Resected High-risk Stage III Melanoma.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-12-01","conditions":"Melanoma","enrollment":39},{"nctId":"NCT03784014","phase":"PHASE3","title":"Molecular Profiling of Advanced Soft-tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2019-10-19","conditions":"Soft Tissue Sarcoma","enrollment":603},{"nctId":"NCT03149029","phase":"PHASE2","title":"Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2017-11-27","conditions":"Metastatic Melanoma","enrollment":16},{"nctId":"NCT04940052","phase":"PHASE3","title":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-11-15","conditions":"Differentiated Thyroid Cancer (DTC)","enrollment":153},{"nctId":"NCT04116541","phase":"PHASE2","title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2020-01-28","conditions":"Malignant Solid Tumor","enrollment":455},{"nctId":"NCT03975231","phase":"PHASE1","title":"Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-09-14","conditions":"BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma","enrollment":6},{"nctId":"NCT01947023","phase":"PHASE1","title":"Dabrafenib and Lapatinib in Treating Patients With Refractory Thyroid Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-09-27","conditions":"Metastatic Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma","enrollment":21},{"nctId":"NCT04544111","phase":"PHASE2","title":"PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-02","conditions":"Thyroid Cancer, Thyroid Cancer, Follicular, Papillary Thyroid Cancer","enrollment":19},{"nctId":"NCT06967155","phase":"PHASE2","title":"A Study of Irinotecan With Dabrafenib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People With Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-03-01","conditions":"Neoplasms","enrollment":23},{"nctId":"NCT02967692","phase":"PHASE3","title":"A Study of the Anti-PD1 Antibody PDR001, in Combination With Dabrafenib and Trametinib in Advanced Melanoma","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-02-17","conditions":"Melanoma","enrollment":568},{"nctId":"NCT07092670","phase":"","title":"MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.","status":"RECRUITING","sponsor":"Intergruppo Melanoma Italiano","startDate":"2025-08-04","conditions":"Melanoma, Fertility","enrollment":270},{"nctId":"NCT04418167","phase":"PHASE1","title":"JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations","status":"SUSPENDED","sponsor":"JS InnoPharm, LLC","startDate":"2020-06-18","conditions":"Solid Tumors","enrollment":71},{"nctId":"NCT05585320","phase":"PHASE1, PHASE2","title":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Immuneering Corporation","startDate":"2022-10-31","conditions":"Advanced Solid Tumor, Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous)","enrollment":209},{"nctId":"NCT01723202","phase":"PHASE2","title":"Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer","status":"COMPLETED","sponsor":"Bhavana Konda","startDate":"2012-11-07","conditions":"Follicular Thyroid Cancer, Insular Thyroid Cancer, Papillary Thyroid Cancer","enrollment":53},{"nctId":"NCT05388877","phase":"PHASE1","title":"E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2022-10-20","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Central Nervous System","enrollment":13},{"nctId":"NCT06195228","phase":"PHASE4","title":"A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2020-01-01","conditions":"Advanced Thyroid Cancer Patients Who Received Target Therapy","enrollment":800},{"nctId":"NCT04238624","phase":"PHASE2","title":"Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-01-20","conditions":"Anaplastic Thyroid Cancer, Thyroid Cancer, BRAF Gene Mutation","enrollment":16},{"nctId":"NCT07022834","phase":"PHASE2","title":"Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children","status":"RECRUITING","sponsor":"West China Second University Hospital","startDate":"2025-06-01","conditions":"Langerhans Cell Histiocytosis (LCH)","enrollment":20},{"nctId":"NCT07010393","phase":"PHASE4","title":"Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2025-07-01","conditions":"Thyroid Neoplasms","enrollment":335},{"nctId":"NCT06712875","phase":"PHASE1, PHASE2","title":"MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2025-04-01","conditions":"Low Grade Glioma, High Grade Glioma","enrollment":27},{"nctId":"NCT06978400","phase":"PHASE2","title":"A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2025-03-01","conditions":"Neoplasms","enrollment":64},{"nctId":"NCT03551626","phase":"PHASE3","title":"Study of Dabrafenib+Trametinib in the Adjuvant Treatment of Stage III BRAF V600+ Melanoma After Complete Resection to Evaluate the Impact on Pyrexia Related Outcomes","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-08-29","conditions":"Malignant Melanoma","enrollment":552},{"nctId":"NCT06119789","phase":"PHASE2","title":"Precision Cancer Therapy in Rare Cancers","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2025-03-20","conditions":"Rare Malignant Neoplasm","enrollment":96},{"nctId":"NCT03944356","phase":"","title":"BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients","status":"COMPLETED","sponsor":"EuMelaReg gGmbH","startDate":"2019-07-01","conditions":"Melanoma","enrollment":232},{"nctId":"NCT05260684","phase":"","title":"Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-01-17","conditions":"Melanoma","enrollment":716},{"nctId":"NCT06819605","phase":"PHASE2, PHASE3","title":"Neoadjuvant Therapy With Conservative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Ameloblastoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2025-03-01","conditions":"Ameloblastoma","enrollment":46},{"nctId":"NCT03026517","phase":"PHASE1","title":"Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-01","conditions":"Melanoma","enrollment":18},{"nctId":"NCT02872259","phase":"PHASE1, PHASE2","title":"BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma","status":"COMPLETED","sponsor":"Haukeland University Hospital","startDate":"2017-02-13","conditions":"Melanoma","enrollment":74},{"nctId":"NCT01902173","phase":"PHASE1, PHASE2","title":"Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-10-08","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Locally Advanced Malignant Solid Neoplasm, Locally Advanced Melanoma","enrollment":27},{"nctId":"NCT06739395","phase":"PHASE2","title":"Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion","status":"RECRUITING","sponsor":"Tianjin Medical University Second Hospital","startDate":"2024-11-01","conditions":"Solid Tumor, Precision Medicine","enrollment":300},{"nctId":"NCT06563999","phase":"PHASE2","title":"Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Lung Cancer Stage III, Mutation","enrollment":120},{"nctId":"NCT06482086","phase":"PHASE2","title":"Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2021-06-01","conditions":"Locally Advanced Thyroid Gland Carcinoma","enrollment":75},{"nctId":"NCT02392871","phase":"PHASE1, PHASE2","title":"Radiotherapy & Combi in Metastatic Melanoma","status":"COMPLETED","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2015-05","conditions":"Metastatic Melanoma","enrollment":10},{"nctId":"NCT04544202","phase":"","title":"Compassionate Use Program BRAF Mutation-positive Patients in the Adjuvant Treatment of Melanoma After Surgical Resection","status":"NO_LONGER_AVAILABLE","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":"Melanoma, Adjuvant","enrollment":""},{"nctId":"NCT04507919","phase":"","title":"Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer","status":"NO_LONGER_AVAILABLE","sponsor":"Novartis Pharmaceuticals","startDate":"","conditions":"Small Cell Lung Carcinoma","enrollment":""},{"nctId":"NCT04652258","phase":"PHASE2","title":"Pyrexia Management Using an IL-6 Antibody in BRAF+ Melanoma Patients Treated with Dabrafenib/ Trametinib +/- Immunotherapy","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2021-02-01","conditions":"Pyrexia","enrollment":20},{"nctId":"NCT04310397","phase":"PHASE2","title":"Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-01-29","conditions":"Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8","enrollment":4},{"nctId":"NCT06653517","phase":"PHASE2","title":"Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma","status":"RECRUITING","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2023-01-01","conditions":"Ameloblastoma, BRAF V600E Mutation Positive","enrollment":12},{"nctId":"NCT02097225","phase":"PHASE1","title":"Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2014-05-29","conditions":"BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Neoplasm","enrollment":22},{"nctId":"NCT06557291","phase":"","title":"Relapse-Free Survival With Adjuvant Dabrafenib/Trametinib Therapy in Patients With BRAF V600-mutated Stage III/IV Melanoma","status":"COMPLETED","sponsor":"Novartis","startDate":"2022-10-04","conditions":"BRAF V600 Mutated-Stage III/IV Melanoma","enrollment":38},{"nctId":"NCT06532149","phase":"","title":"ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-08-05","conditions":"NSCLC Stage IV, Sex Disorder, Hypogonadism, Male","enrollment":80},{"nctId":"NCT03455764","phase":"PHASE1, PHASE2","title":"MCS110 With BRAF/MEK Inhibition in Patients With Melanoma","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2018-09-10","conditions":"Melanoma","enrollment":6},{"nctId":"NCT05159245","phase":"PHASE2","title":"The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs","status":"RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2021-12-10","conditions":"Advanced Cancer, Solid Tumor, Haematological Malignancy","enrollment":250},{"nctId":"NCT02700763","phase":"NA","title":"[18F]Dabrafenib Molecular Imaging in Melanoma Brain Metastasis","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2016-12-06","conditions":"Melanoma","enrollment":1},{"nctId":"NCT06362694","phase":"PHASE2","title":"Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy","status":"RECRUITING","sponsor":"Saint Petersburg State University, Russia","startDate":"2024-03-25","conditions":"Anaplastic Thyroid Cancer","enrollment":10},{"nctId":"NCT06337617","phase":"","title":"A Multi-center Retrospective Study With Secondary Use of Data of Tafinlar (Dabrafenib) Plus Mekinist (Trametinib) in Chinese Patients With BRAF V600 Mutation Positive Melanoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-05-10","conditions":"BRAF V600 Mutation Positive Melanoma","enrollment":90},{"nctId":"NCT04739566","phase":"PHASE2","title":"Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer","status":"WITHDRAWN","sponsor":"Saint Petersburg State University, Russia","startDate":"2021-01-22","conditions":"Thyroid Gland Anaplastic Carcinoma","enrollment":""},{"nctId":"NCT04949113","phase":"PHASE3","title":"Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2021-07-08","conditions":"Malignant Melanoma Stage III","enrollment":423},{"nctId":"NCT03878524","phase":"PHASE1","title":"Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2020-04-01","conditions":"Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia","enrollment":2},{"nctId":"NCT04817956","phase":"PHASE2","title":"Improving Public Cancer Care by Implementing Precision Medicine in Norway","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-04-01","conditions":"Cancer Metastatic","enrollment":3000},{"nctId":"NCT06264778","phase":"PHASE3","title":"Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2024-03-01","conditions":"Ameloblastoma","enrollment":10},{"nctId":"NCT05525273","phase":"PHASE2","title":"Treatment of BRAF ( B-Rapidly Accelerated Fibrosarcoma) Mutated Papillary Craniopharyngioma","status":"RECRUITING","sponsor":"Eva Marie Erfurth, MD, PhD","startDate":"2023-09-01","conditions":"Craniopharyngioma","enrollment":25},{"nctId":"NCT02367859","phase":"PHASE2","title":"Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma","status":"COMPLETED","sponsor":"Stanford University","startDate":"2017-07-17","conditions":"Ameloblastoma, BRAF Gene Mutation","enrollment":1},{"nctId":"NCT02925234","phase":"PHASE2","title":"The Drug Rediscovery Protocol (DRUP Trial)","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2016-08","conditions":"Cancer, Tumors, Neoplasm","enrollment":1550},{"nctId":"NCT05432622","phase":"","title":"A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-12-19","conditions":"Melanoma","enrollment":95},{"nctId":"NCT02684058","phase":"PHASE2","title":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Pediatric Patients With BRAF V600 Mutation Positive LGG or Relapsed or Refractory HGG Tumors","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-12-28","conditions":"Diffuse Astrocytoma, Anaplastic Astrocytoma, Astrocytoma","enrollment":151},{"nctId":"NCT02382549","phase":"EARLY_PHASE1","title":"A Clinical Trial to Evaluate a Melanoma Helper Peptide Vaccine Plus Dabrafenib and Trametinib","status":"TERMINATED","sponsor":"Craig L Slingluff, Jr","startDate":"2016-04","conditions":"Melanoma","enrollment":8},{"nctId":"NCT05876806","phase":"PHASE2","title":"Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations","status":"RECRUITING","sponsor":"Se Jun Park","startDate":"2023-06-20","conditions":"Cancer","enrollment":30},{"nctId":"NCT02143050","phase":"PHASE1, PHASE2","title":"Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients","status":"WITHDRAWN","sponsor":"University of Louisville","startDate":"2014-09","conditions":"Melanoma","enrollment":""},{"nctId":"NCT05182931","phase":"PHASE2","title":"A Prospective, Multi-Centre Trial of TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer (I-FIRST Study)","status":"UNKNOWN","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2022-07-14","conditions":"Thyroid Cancer","enrollment":80},{"nctId":"NCT05370807","phase":"PHASE2","title":"A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma","status":"UNKNOWN","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2022-10-03","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":48},{"nctId":"NCT05988697","phase":"","title":"Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2023-11-01","conditions":"NSCLC, BRAF V600E Mutation, Advanced Cancer","enrollment":36},{"nctId":"NCT06079333","phase":"PHASE2","title":"NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2023-01-01","conditions":"Anaplastic Thyroid Cancer","enrollment":20},{"nctId":"NCT06054191","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Targeted Treatment in NSCLC With BRAF V600 or MET Exon 14 Mutations","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-02-01","conditions":"NSCLC, BRAF V600 Mutation, MET Exon 14 Mutation","enrollment":40},{"nctId":"NCT03593993","phase":"","title":"A Biospecimen Collection Study in BRAF-V600E Mutated Recurrent Gliomas","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-05-19","conditions":"Glioma, BRAF V600E, Pleomorphic Xantho-Astrocytoma","enrollment":3},{"nctId":"NCT04059224","phase":"PHASE2","title":"TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma","status":"COMPLETED","sponsor":"Universitair Ziekenhuis Brussel","startDate":"2019-01-28","conditions":"Stage IV Melanoma, Stage III Melanoma","enrollment":45},{"nctId":"NCT03272464","phase":"PHASE1","title":"INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.","status":"TERMINATED","sponsor":"Massachusetts General Hospital","startDate":"2019-05-29","conditions":"Melanoma","enrollment":1},{"nctId":"NCT05299580","phase":"PHASE2","title":"\"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)\"","status":"WITHDRAWN","sponsor":"Fondazione Melanoma Onlus","startDate":"2021-02-18","conditions":"Melanoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":34,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dabrafenib"],"phase":"phase_3","status":"active","brandName":"GSK2118436","genericName":"GSK2118436","companyName":"M.D. Anderson Cancer Center","companyId":"m-d-anderson-cancer-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK2118436 is a BRAF V600E inhibitor that blocks mutant BRAF kinase signaling in melanoma cells. Used for Metastatic melanoma with BRAF V600E mutation, Unresectable melanoma with BRAF V600E mutation.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":8,"withResults":3},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}